Insilico Medicine starts Phase III of rentosertib (ISM001-055) for IPF
Insilico Medicine initiated a Phase III trial of rentosertib, its AI-discovered TNIK inhibitor, for idiopathic pulmonary fibrosis — the first Phase III for a generative-AI-discovered drug.
On 2026-07-07, the verified AI news record added a significant robotics, science & health development: Insilico Medicine initiated a Phase III trial of rentosertib, its AI-discovered TNIK inhibitor, for idiopathic pulmonary fibrosis — the first Phase III for a generative-AI-discovered drug.
Context
Insilico Medicine initiated a Phase III trial of rentosertib, its AI-discovered TNIK inhibitor, for idiopathic pulmonary fibrosis — the first Phase III for a generative-AI-discovered drug. Defining AI-drug-discovery validation milestone; Phase IIa data published in Nature Medicine (2025). Watch for dosing start and sites.
What changed
Insilico Medicine initiated a Phase III trial of rentosertib, its AI-discovered TNIK inhibitor, for idiopathic pulmonary fibrosis — the first Phase III for a generative-AI-discovered drug. The primary supporting record is appliedxl.com.
Why it matters
Defining AI-drug-discovery validation milestone; Phase IIa data published in Nature Medicine (2025). Watch for dosing start and sites. The applied-AI angle matters because physical and scientific deployments test whether models can produce reliable outcomes outside chat and coding environments.
Details
The research file records the item under “Insilico Medicine starts Phase III of rentosertib (ISM001-055) for IPF” with source timing of Jul 7, 2026. The captured research confidence note is: High. Defining AI-drug-discovery validation milestone; Phase IIa data published in Nature Medicine (2025). Watch for dosing start and sites.
Limitations and caveats
The research file did not identify a blocking caveat, but vendor-supplied claims should still be read as company statements unless independently confirmed.
Sources
Update note: Last reviewed 2026-07-22. Next checkpoint: monitor official channels and the linked source record.
Sources
- appliedxl.com — aggregator
Drafted with AI assistance from source briefs; reviewed for citation completeness and label accuracy.